Data as of 11:27am ET
| -0.10 / -4.35%|
MediciNova, Inc. operates as a development stage biopharmaceutical company with interest in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The company's development pipeline consists of six product development programs which have been in clinical development for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in San Diego, CA.
|Yuichi Iwaki||President, CEO, CFO, Director & CAO|
|Kazuko Matsuda||Chief Medical Officer|
|Masatsune Okajima||Vice President & Head-Japanese Office|
|Geoffrey G. O'Brien||Vice President|
|Mark Johnson||Director-Investor Relations & Development|